ATE340572T1 - Benzazole derivate zur behandlung von scleroderma - Google Patents

Benzazole derivate zur behandlung von scleroderma

Info

Publication number
ATE340572T1
ATE340572T1 AT02787919T AT02787919T ATE340572T1 AT E340572 T1 ATE340572 T1 AT E340572T1 AT 02787919 T AT02787919 T AT 02787919T AT 02787919 T AT02787919 T AT 02787919T AT E340572 T1 ATE340572 T1 AT E340572T1
Authority
AT
Austria
Prior art keywords
scleroderma
treatment
benzazole derivatives
fibrosis
dupuytren
Prior art date
Application number
AT02787919T
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Pascale Gaillard
Yolande Chvatchko
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE340572T1 publication Critical patent/ATE340572T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT02787919T 2001-12-07 2002-12-06 Benzazole derivate zur behandlung von scleroderma ATE340572T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01000727 2001-12-07

Publications (1)

Publication Number Publication Date
ATE340572T1 true ATE340572T1 (de) 2006-10-15

Family

ID=8176107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787919T ATE340572T1 (de) 2001-12-07 2002-12-06 Benzazole derivate zur behandlung von scleroderma

Country Status (13)

Country Link
US (1) US7776854B2 (de)
EP (1) EP1450792B1 (de)
JP (2) JP4589002B2 (de)
AT (1) ATE340572T1 (de)
AU (1) AU2002352227B2 (de)
CA (1) CA2468826C (de)
DE (1) DE60215042T2 (de)
DK (1) DK1450792T3 (de)
ES (1) ES2268127T3 (de)
IL (1) IL162259A0 (de)
PT (1) PT1450792E (de)
SI (1) SI1450792T1 (de)
WO (1) WO2003047570A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696909B1 (de) * 2003-09-12 2007-11-14 Laboratoires Serono SA Benzothiazol-derivate zur behandlung von diabetes
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US20070203134A1 (en) * 2004-09-10 2007-08-30 Applied Research Systems Ars Holding N.V. Benzimidazole Acetonitriles
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
ATE411817T1 (de) * 2004-11-17 2008-11-15 Ares Trading Sa Benzothiazolformulierungen und ihre verwendung
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EP2026802A2 (de) * 2006-06-02 2009-02-25 Laboratoires Serono SA Jnk-hemmer zur behandlung von hautkrankheiten
US20080305186A1 (en) * 2007-06-11 2008-12-11 Board Of Regents, The University Of Texas System Method and Composition for the Treatment of Cardiac Hypertrophy
WO2009140433A1 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of promoting wound healing
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0666812B2 (ja) 1988-01-11 1994-08-24 日本電気株式会社 パケット交換方法並びにパケット交換装置
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
AU5316900A (en) * 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
EP1110957A1 (de) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazolderivate und ihre Verwendung als JNK Modulatoren
MXPA03005001A (es) * 2000-12-05 2003-09-05 Vertex Pharma Inhibidores de n- terminal c-jun cinasas (jnk) y otras proteinas cinasas.

Also Published As

Publication number Publication date
CA2468826A1 (en) 2003-06-12
PT1450792E (pt) 2006-12-29
SI1450792T1 (sl) 2006-12-31
US7776854B2 (en) 2010-08-17
CA2468826C (en) 2011-11-01
DE60215042D1 (de) 2006-11-09
AU2002352227B2 (en) 2007-11-01
AU2002352227A1 (en) 2003-06-17
US20050119277A1 (en) 2005-06-02
EP1450792A1 (de) 2004-09-01
DK1450792T3 (da) 2007-01-29
JP4589002B2 (ja) 2010-12-01
WO2003047570A1 (en) 2003-06-12
EP1450792B1 (de) 2006-09-27
IL162259A0 (en) 2005-11-20
DE60215042T2 (de) 2007-10-04
ES2268127T3 (es) 2007-03-16
JP2005515994A (ja) 2005-06-02
JP2010248205A (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
SE9604786D0 (sv) New compounds
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE60215042D1 (de) Benzazole derivate zur behandlung von scleroderma
BR0014076A (pt) Benzamidas e inibidores correlatos do fator xa
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
CY1111693T1 (el) Αντιιικοι παραγοντες
EP1426375A3 (de) Analgetische Spiroindolderivate
SE9800836D0 (sv) New Compounds
NO20030411D0 (no) Farmasöytiske sammensetninger for behandlingen av smertefulle, inflammatoriske og ulceröse tilstander av fuktige epiteloverflater slik sommukositt, stomatitt og Behcets syndrom
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
EP1251126A3 (de) Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
SE9900961D0 (sv) Novel compounds
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
NZ513096A (en) Compositions for treating inflammatory response
SE9802794D0 (sv) New compounds
DE602004007268D1 (de) CYCLOALKYLSULFANYL-SUBSTITUIERTE BENZOiBöTHIOPHENE ALS THERAPEUTISCHE MITTEL
BR0010546A (pt) Terapia antiinflamatória para infecção mediada inflamatória
SE9902267D0 (sv) New compounds
SE9802793D0 (sv) New compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1450792

Country of ref document: EP

EEFA Change of the company name